These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 25055035)

  • 21. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
    Schulze-Koops H; Skapenko A
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
    Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
    Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases.
    Rinaudo-Gaujous M; Paul S; Tedesco ED; Genin C; Roblin X; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2013 Oct; 38(8):914-24. PubMed ID: 24001128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PANLAR consensus statement on biosimilars.
    Kowalski SC; Benavides JA; Roa PAB; Galarza-Maldonado C; Caballero-Uribe CV; Soriano ER; Pineda C; Azevedo VF; Avila-Pedretti G; Babini AM; Cachafeiro-Vilar A; Cifuentes-Alvarado M; Cohen SB; Díaz PE; Soto LD; Encalada C; Garro B; Sariego IAG; Guibert-Toledano M; Rodriguez VJK; Lopez MEL; Ortega AP; Russell AS; Santos-Moreno P; Terán IS; Vargas A; Vásquez G; Xavier RM; Firedman DXX; Mysler E; Kay J
    Clin Rheumatol; 2019 May; 38(5):1485-1496. PubMed ID: 30915652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilars in pediatric rheumatology and their introduction into routine care.
    Aragon Cuevas O; Hedrich CM
    Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Biosimilars in rheumatology. Development and results of clinical trials].
    Alten R
    Z Rheumatol; 2015 Oct; 74(8):682-8. PubMed ID: 26347121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
    Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
    BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilars: how similar?
    Strand V; Cronstein B
    Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current state of biosimilars in Mexico: The position of the Mexican College of Rheumatology, 2016.
    Xibille D; Carrillo S; Huerta-Sil G; Hernández R; Limón L; Olvera-Soto G; Jara-Quezada LJ; Esquivel A; Pérez-Rodríguez M
    Reumatol Clin (Engl Ed); 2018; 14(3):127-136. PubMed ID: 28807650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.
    Mellstedt H
    Ann Oncol; 2013 Sep; 24 Suppl 5():v23-8. PubMed ID: 23975701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of biosimilars in oncology.
    Schellekens H; Smolen JS; Dicato M; Rifkin RM
    Lancet Oncol; 2016 Nov; 17(11):e502-e509. PubMed ID: 27819248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From bioequivalence to biosimilars: How much do regulators dare?
    Weise M
    Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
    Kim WS; Coiffier B; Kwon HC; Kim S
    Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
    El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H
    Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilars vs originators: Are they the same?
    Sarzi-Puttini P; Marotto D; Caporali R; Galeazzi M; Atzeni F; Hamar A; Soós B; Szekanecz Z
    Autoimmun Rev; 2019 Dec; 18(12):102404. PubMed ID: 31639517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biosimilars--opportunity or threat?].
    Swierkot J
    Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilars in rheumatology: understanding the rigor of their development.
    Goel N; Chance K
    Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilars: Concepts and controversies.
    Gámez-Belmonte R; Hernández-Chirlaque C; Arredondo-Amador M; Aranda CJ; González R; Martínez-Augustin O; Sánchez de Medina F
    Pharmacol Res; 2018 Jul; 133():251-264. PubMed ID: 29428205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.